Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 394 entries
Sorted by: Best Match Show Resources per page
Safety of rhGH, Early vs Late: the Hare Seems Fine, but What About the Tortoise?.

The Journal of clinical endocrinology and metabolism

Rogol AD.
PMID: 34963134
J Clin Endocrinol Metab. 2021 May 13;106(6):e2450-e2451. doi: 10.1210/clinem/dgab116.

No abstract available.

Cite
Rogol AD. Safety of rhGH, Early vs Late: the Hare Seems Fine, but What About the Tortoise?. J Clin Endocrinol Metab. 2021;106(6):e2450-e2451doi: 10.1210/clinem/dgab116.
Rogol, A. D. (2021). Safety of rhGH, Early vs Late: the Hare Seems Fine, but What About the Tortoise?. The Journal of clinical endocrinology and metabolism, 106(6), e2450-e2451. https://doi.org/10.1210/clinem/dgab116
Rogol, Alan D. "Safety of rhGH, Early vs Late: the Hare Seems Fine, but What About the Tortoise?." The Journal of clinical endocrinology and metabolism vol. 106,6 (2021): e2450-e2451. doi: https://doi.org/10.1210/clinem/dgab116
Rogol AD. Safety of rhGH, Early vs Late: the Hare Seems Fine, but What About the Tortoise?. J Clin Endocrinol Metab. 2021 May 13;106(6):e2450-e2451. doi: 10.1210/clinem/dgab116. PMID: 34963134.
Copy Download .nbib Format: NLM
Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study.

International journal of pediatric endocrinology

Angulo M, Abuzzahab MJ, Pietropoli A, Ostrow V, Kelepouris N, Tauber M.
PMID: 33292530
Int J Pediatr Endocrinol. 2020 Nov 10;2020(1):20. doi: 10.1186/s13633-020-00090-6.

BACKGROUND: Growth hormone (GH) deficiency is common in patients with Prader-Willi syndrome (PWS) and leads to short adult stature. The current study assessed clinical outcomes based on real-world observational data in pediatric patients with PWS who were treated with...

Cite
Angulo M, Abuzzahab MJ, Pietropoli A, et al. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study. Int J Pediatr Endocrinol. 2020;2020(1):20doi: 10.1186/s13633-020-00090-6.
Angulo, M., Abuzzahab, M. J., Pietropoli, A., Ostrow, V., Kelepouris, N., & Tauber, M. (2020). Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study. International journal of pediatric endocrinology, 2020(1), 20. https://doi.org/10.1186/s13633-020-00090-6
Angulo, Moris, et al. "Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study." International journal of pediatric endocrinology vol. 2020,1 (2020): 20. doi: https://doi.org/10.1186/s13633-020-00090-6
Angulo M, Abuzzahab MJ, Pietropoli A, Ostrow V, Kelepouris N, Tauber M. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study. Int J Pediatr Endocrinol. 2020 Nov 10;2020(1):20. doi: 10.1186/s13633-020-00090-6. PMID: 33292530; PMCID: PMC7653711.
Copy Download .nbib Format: NLM
Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program.

International journal of pediatric endocrinology

Miller BS, Ross J, Ostrow V.
PMID: 33042202
Int J Pediatr Endocrinol. 2020;2020:19. doi: 10.1186/s13633-020-00089-z. Epub 2020 Oct 06.

BACKGROUND: Treatment of children with growth hormone deficiency (GHD) or idiopathic short stature (ISS) using GH is only effective for bone growth prior to epiphyseal fusion. Aromatase inhibitor therapy (AIT) blocks estrogen production, thereby delaying epiphyseal fusion. The current...

Cite
Miller BS, Ross J, Ostrow V. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. Int J Pediatr Endocrinol. 2020;2020:19doi: 10.1186/s13633-020-00089-z.
Miller, B. S., Ross, J., & Ostrow, V. (2020). Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. International journal of pediatric endocrinology, 202019. https://doi.org/10.1186/s13633-020-00089-z
Miller, Bradley S, et al. "Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program." International journal of pediatric endocrinology vol. 2020 (2020): 19. doi: https://doi.org/10.1186/s13633-020-00089-z
Miller BS, Ross J, Ostrow V. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program. Int J Pediatr Endocrinol. 2020;2020:19. doi: 10.1186/s13633-020-00089-z. Epub 2020 Oct 06. PMID: 33042202; PMCID: PMC7537098.
Copy Download .nbib Format: NLM
[Growth hormone deficit: Influence of puberty on the response to treatment].

Anales de pediatria

Sánchez Malo MJ, Hidalgo Sanz J, Hernández Tejedor C, García Ventura M, Ferrer Lozano M, Labarta Aizpún JI, de Arriba Muñoz A.
PMID: 33994327
An Pediatr (Engl Ed). 2021 May 13; doi: 10.1016/j.anpedi.2021.04.003. Epub 2021 May 13.

INTRODUCTION: Short stature is the most frequent reason for consultation in Pediatric Endocrinology consultations and sometimes requires treatment with growth hormone. The aim of the study was to analyze the response to treatment based on its onset in pubertal...

Cite
Sánchez Malo MJ, Hidalgo Sanz J, Hernández Tejedor C, et al. Déficit de hormona de crecimiento: influencia de la pubertad en la respuesta al tratamiento. [Growth hormone deficit: Influence of puberty on the response to treatment]. An Pediatr (Engl Ed). 2021;doi: 10.1016/j.anpedi.2021.04.003.
Sánchez Malo, M. J., Hidalgo Sanz, J., Hernández Tejedor, C., García Ventura, M., Ferrer Lozano, M., Labarta Aizpún, J. I., & de Arriba Muñoz, A. (2021). Déficit de hormona de crecimiento: influencia de la pubertad en la respuesta al tratamiento. [Growth hormone deficit: Influence of puberty on the response to treatment]. Anales de pediatria, . https://doi.org/10.1016/j.anpedi.2021.04.003
Sánchez Malo, María José, et al. "Déficit de hormona de crecimiento: influencia de la pubertad en la respuesta al tratamiento." [Growth hormone deficit: Influence of puberty on the response to treatment]. Anales de pediatria vol. (2021). doi: https://doi.org/10.1016/j.anpedi.2021.04.003
Sánchez Malo MJ, Hidalgo Sanz J, Hernández Tejedor C, García Ventura M, Ferrer Lozano M, Labarta Aizpún JI, de Arriba Muñoz A. Déficit de hormona de crecimiento: influencia de la pubertad en la respuesta al tratamiento. [Growth hormone deficit: Influence of puberty on the response to treatment]. An Pediatr (Engl Ed). 2021 May 13; doi: 10.1016/j.anpedi.2021.04.003. Epub 2021 May 13. Spanish. PMID: 33994327.
Copy Download .nbib Format: NLM
Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa.

P & T : a peer-reviewed journal for formulary management

Flynn A, Lincoln J, Burke M.
PMID: 27313436
P T. 2016 Jun;41(6):381-4.

The authors examine the role that unregulated dietary supplements may have had in a young man who presented with psychotic and homicidal ideations.

Cite
Flynn A, Lincoln J, Burke M. Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa. P T. 2016;41(6):381-4
Flynn, A., Lincoln, J., & Burke, M. (2016). Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa. P & T : a peer-reviewed journal for formulary management, 41(6), 381-4.
Flynn, Alexandra, et al. "Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa." P & T : a peer-reviewed journal for formulary management vol. 41,6 (2016): 381-4.
Flynn A, Lincoln J, Burke M. Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa. P T. 2016 Jun;41(6):381-4. PMID: 27313436; PMCID: PMC4894515.
Copy Download .nbib Format: NLM
EVALUATION OF FIRST YEAR RESPONSE TO TREATMENT IN CASES WITH GROWTH HORMONE DEFICIENCY.

Acta endocrinologica (Bucharest, Romania : 2005)

Kör Y, Keskin M.
PMID: 31149129
Acta Endocrinol (Buchar). 2016 Oct-Dec;12(4):443-449. doi: 10.4183/aeb.2016.443.

BACKGROUND/AIMS: Growth hormone (GH) treatment has severe cost burden on patients, their families, and healthcare systems. Therefore, accuracy of diagnosis should be confirmed; factors affecting the response to treatment should be defined. The present study is performed to evaluate...

Cite
Kör Y, Keskin M. EVALUATION OF FIRST YEAR RESPONSE TO TREATMENT IN CASES WITH GROWTH HORMONE DEFICIENCY. Acta Endocrinol (Buchar). 2016;12(4):443-449doi: 10.4183/aeb.2016.443.
Kör, Y., & Keskin, M. (2016). EVALUATION OF FIRST YEAR RESPONSE TO TREATMENT IN CASES WITH GROWTH HORMONE DEFICIENCY. Acta endocrinologica (Bucharest, Romania : 2005), 12(4), 443-449. https://doi.org/10.4183/aeb.2016.443
Kör, Y, and Keskin, M. "EVALUATION OF FIRST YEAR RESPONSE TO TREATMENT IN CASES WITH GROWTH HORMONE DEFICIENCY." Acta endocrinologica (Bucharest, Romania : 2005) vol. 12,4 (2016): 443-449. doi: https://doi.org/10.4183/aeb.2016.443
Kör Y, Keskin M. EVALUATION OF FIRST YEAR RESPONSE TO TREATMENT IN CASES WITH GROWTH HORMONE DEFICIENCY. Acta Endocrinol (Buchar). 2016 Oct-Dec;12(4):443-449. doi: 10.4183/aeb.2016.443. PMID: 31149129; PMCID: PMC6535253.
Copy Download .nbib Format: NLM
Sleep deprivation and diet affect human GH gene expression in transgenic mice in vivo.

Endocrine connections

Jarmasz JS, Jin Y, Vakili H, Cattini PA.
PMID: 33112821
Endocr Connect. 2020 Dec;9(12):1135-1147. doi: 10.1530/EC-20-0354.

Human (h) growth hormone (GH) production studies are largely limited to effects on secretion. How pituitary hGH gene (hGH-N/GH1) expression is regulated is important in our understanding of the role hGH plays in physiology and disease. Here we assess...

Cite
Jarmasz JS, Jin Y, Vakili H, et al. Sleep deprivation and diet affect human GH gene expression in transgenic mice in vivo. Endocr Connect. 2020;9(12):1135-1147doi: 10.1530/EC-20-0354.
Jarmasz, J. S., Jin, Y., Vakili, H., & Cattini, P. A. (2020). Sleep deprivation and diet affect human GH gene expression in transgenic mice in vivo. Endocrine connections, 9(12), 1135-1147. https://doi.org/10.1530/EC-20-0354
Jarmasz, Jessica S, et al. "Sleep deprivation and diet affect human GH gene expression in transgenic mice in vivo." Endocrine connections vol. 9,12 (2020): 1135-1147. doi: https://doi.org/10.1530/EC-20-0354
Jarmasz JS, Jin Y, Vakili H, Cattini PA. Sleep deprivation and diet affect human GH gene expression in transgenic mice in vivo. Endocr Connect. 2020 Dec;9(12):1135-1147. doi: 10.1530/EC-20-0354. PMID: 33112821; PMCID: PMC7774756.
Copy Download .nbib Format: NLM
Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program.

International journal of pediatric endocrinology

Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, Christesen HT.
PMID: 26351466
Int J Pediatr Endocrinol. 2015;2015(1):17. doi: 10.1186/s13633-015-0015-1. Epub 2015 Sep 08.

BACKGROUND: Turner syndrome (TS) and Noonan syndrome (NS) are distinct syndromes associated with short stature and other similar phenotypic features. We compared the responses to growth hormone (GH) therapy of TS and NS patients enrolled in the NordiNet® International...

Cite
Lee PA, Ross JL, Pedersen BT, et al. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program. Int J Pediatr Endocrinol. 2015;2015(1):17doi: 10.1186/s13633-015-0015-1.
Lee, P. A., Ross, J. L., Pedersen, B. T., Kotnik, P., Germak, J. A., & Christesen, H. T. (2015). Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program. International journal of pediatric endocrinology, 2015(1), 17. https://doi.org/10.1186/s13633-015-0015-1
Lee, Peter A, et al. "Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program." International journal of pediatric endocrinology vol. 2015,1 (2015): 17. doi: https://doi.org/10.1186/s13633-015-0015-1
Lee PA, Ross JL, Pedersen BT, Kotnik P, Germak JA, Christesen HT. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program. Int J Pediatr Endocrinol. 2015;2015(1):17. doi: 10.1186/s13633-015-0015-1. Epub 2015 Sep 08. PMID: 26351466; PMCID: PMC4562101.
Copy Download .nbib Format: NLM
Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.

Pituitary

Biller BMK, Höybye C, Carroll P, Gordon MB, Birkegård AC, Kelepouris N, Nedjatian N, Weber MM.
PMID: 33709288
Pituitary. 2021 Aug;24(4):611-621. doi: 10.1007/s11102-021-01138-3. Epub 2021 Mar 12.

PURPOSE: Data on the safety of growth hormone (GH) replacement therapy during pregnancy are limited. We report a combined analysis of data from pregnant women treated with GH while enrolled in two non-interventional, multicenter studies: NordiNet® International Outcome Study...

Cite
Biller BMK, Höybye C, Carroll P, et al. Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program. Pituitary. 2021;24(4):611-621doi: 10.1007/s11102-021-01138-3.
Biller, B. M. K., Höybye, C., Carroll, P., Gordon, M. B., Birkegård, A. C., Kelepouris, N., Nedjatian, N., & Weber, M. M. (2021). Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program. Pituitary, 24(4), 611-621. https://doi.org/10.1007/s11102-021-01138-3
Biller, Beverly M K, et al. "Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program." Pituitary vol. 24,4 (2021): 611-621. doi: https://doi.org/10.1007/s11102-021-01138-3
Biller BMK, Höybye C, Carroll P, Gordon MB, Birkegård AC, Kelepouris N, Nedjatian N, Weber MM. Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program. Pituitary. 2021 Aug;24(4):611-621. doi: 10.1007/s11102-021-01138-3. Epub 2021 Mar 12. PMID: 33709288; PMCID: PMC8270875.
Copy Download .nbib Format: NLM
Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism.

Frontiers in veterinary science

Načeradská M, Návojová Horáčková K, Fridrichová M.
PMID: 34881322
Front Vet Sci. 2021 Nov 22;8:773355. doi: 10.3389/fvets.2021.773355. eCollection 2021.

A 6-month-old kitten, male, domestic shorthair cat was presented with dwarfism, ocular and nasal discharge, and

Cite
Načeradská M, Návojová Horáčková K, Fridrichová M. Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism. Front Vet Sci. 2021;8:773355doi: 10.3389/fvets.2021.773355.
Načeradská, M., Návojová Horáčková, K., & Fridrichová, M. (2021). Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism. Frontiers in veterinary science, 8773355. https://doi.org/10.3389/fvets.2021.773355
Načeradská, Martina, et al. "Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism." Frontiers in veterinary science vol. 8 (2021): 773355. doi: https://doi.org/10.3389/fvets.2021.773355
Načeradská M, Návojová Horáčková K, Fridrichová M. Case Report: Human Recombinant Growth Hormone Therapy in a DSH Cat Presented With Dwarfism. Front Vet Sci. 2021 Nov 22;8:773355. doi: 10.3389/fvets.2021.773355. eCollection 2021. PMID: 34881322; PMCID: PMC8645647.
Copy Download .nbib Format: NLM
Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients.

Medical devices (Auckland, N.Z.)

Schnabel D, Partsch CJ, Houang M, Ehtisham S, Johnstone H, Zabransky M, Kiess W.
PMID: 27660496
Med Devices (Auckl). 2016 Sep 07;9:317-24. doi: 10.2147/MDER.S115933. eCollection 2016.

BACKGROUND: A questionnaire-based survey was conducted to assess attitudes toward a reusable self-injection system (SurePal™) among pediatric patients with growth disturbances who were prescribed treatment with Omnitrope(®) within routine clinical practice.METHODS: This was a multicenter, observational study, incorporated into...

Cite
Schnabel D, Partsch CJ, Houang M, et al. Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients. Med Devices (Auckl). 2016;9:317-24doi: 10.2147/MDER.S115933.
Schnabel, D., Partsch, C. J., Houang, M., Ehtisham, S., Johnstone, H., Zabransky, M., & Kiess, W. (2016). Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients. Medical devices (Auckland, N.Z.), 9317-24. https://doi.org/10.2147/MDER.S115933
Schnabel, Dirk, et al. "Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients." Medical devices (Auckland, N.Z.) vol. 9 (2016): 317-24. doi: https://doi.org/10.2147/MDER.S115933
Schnabel D, Partsch CJ, Houang M, Ehtisham S, Johnstone H, Zabransky M, Kiess W. Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients. Med Devices (Auckl). 2016 Sep 07;9:317-24. doi: 10.2147/MDER.S115933. eCollection 2016. PMID: 27660496; PMCID: PMC5019470.
Copy Download .nbib Format: NLM
Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module.

International immunopharmacology

Zaky DA, Eldehna WM, El Kerdawy AM, Abdallah DM, El Abhar HS, Wadie W.
PMID: 34794887
Int Immunopharmacol. 2021 Dec;101:108370. doi: 10.1016/j.intimp.2021.108370. Epub 2021 Nov 15.

Septic encephalopathy results from the intense reaction of the immune system to infection. The role of growth hormone (GH) signaling in maintaining brain function is well established; however, the involvement of the vascular endothelial growth factor receptor-2 (VEGFR2) in...

Cite
Zaky DA, Eldehna WM, El Kerdawy AM, et al. Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module. Int Immunopharmacol. 2021;101:108370doi: 10.1016/j.intimp.2021.108370.
Zaky, D. A., Eldehna, W. M., El Kerdawy, A. M., Abdallah, D. M., El Abhar, H. S., & Wadie, W. (2021). Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module. International immunopharmacology, 101108370. https://doi.org/10.1016/j.intimp.2021.108370
Zaky, Doaa A, et al. "Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module." International immunopharmacology vol. 101 (2021): 108370. doi: https://doi.org/10.1016/j.intimp.2021.108370
Zaky DA, Eldehna WM, El Kerdawy AM, Abdallah DM, El Abhar HS, Wadie W. Recombinant human growth hormone improves the immune status of rats with septic encephalopathy: The role of VEGFR2 in the prevalence of endoplasmic reticulum stress repair module. Int Immunopharmacol. 2021 Dec;101:108370. doi: 10.1016/j.intimp.2021.108370. Epub 2021 Nov 15. PMID: 34794887.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 394 entries